

# Nerve Growth Factor and Alzheimers Disease

Medhane G Cumbay\*

Department of Pharmacology, Butler University, USA

## Abstract

Whim-whams growth factor (NGF) is a well- characterized protein that exerts pharmacological goods on a group of cholinergic neurons known to atrophy in Alzheimer's complaint (announcement). Considerable substantiation from beast studies suggests that NGF may be useful in reversing, halting, or at least decelerating the progression of associated with the complaint.

## Introduction

The Nerve Growth Factor (NGF) is a well-characterized protein that exerts pharmacological effects on a group of cholinergic neurons known to atrophy in Alzheimer's disease (AD). Considerable substantiation from animal studies suggests that NGF may be useful in reversing, halting, or at least decelerating the progression of AD associated with the complaint.

NGF is a member of the neurotrophin family of growth factors. It is secreted by various cell types, including neurons, and binds to specific receptors on the surface of target cells. This binding triggers a cascade of intracellular signaling events that lead to cell survival, proliferation, and differentiation.

In the context of AD, NGF has been shown to have neuroprotective effects. It can promote the survival of cholinergic neurons, which are the primary cell type affected in AD. Additionally, NGF has been shown to enhance the synthesis and release of acetylcholine, a neurotransmitter that is deficient in AD.

Several studies have demonstrated that NGF treatment can improve cognitive function in animal models of AD. For example, NGF treatment has been shown to increase the number of cholinergic neurons in the hippocampus and to improve performance on memory tasks.

These findings suggest that NGF may be a promising therapeutic target for AD. However, further research is needed to determine the optimal dose and route of administration for NGF in AD patients. Additionally, it is important to investigate the long-term effects of NGF treatment and to ensure that it is safe and effective for use in humans.

\*Corresponding author: Medhane G Cumbay, Department of Pharmacology, Butler University, USA, E-mail: Medhane.G\_Cumbay@gmail.com

Received: 1-Oct-2022, Manuscript No: cpb-22-77171; Editor assigned: 3-Oct-2022, Pre-QC No: cpb-22-77171(PQ); Reviewed: 17-Oct-2022, QC No: cpb-22-77171; Revised: 20-Oct-2022, Manuscript No: cpb-22-77171 (R); Published: 31-Oct-2022, DOI: 10.4172/2167-065X.1000293

Citation: Cumbay MG (2022) Nerve Growth Factor and Alzheimers Disease. Clin Pharmacol Biopharm, 11: 293.

Copyright: © 2022 Cumbay MG. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

## Discussion

16  
36 1 2